摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-甲基-10H-苯并[b]噻吩并[2,3-e][1,4]二氮杂革-4-胺 | 612503-08-9

中文名称
2-甲基-10H-苯并[b]噻吩并[2,3-e][1,4]二氮杂革-4-胺
中文别名
2-甲基-10H-噻吩并[2,3-B][1,5]苯并二氮杂环庚烷-4-胺
英文名称
2-methyl-10H-benzo[b]thieno[2,3-e][1,4]diazepin-4-amine
英文别名
4-amino-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepine;2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-amine
2-甲基-10H-苯并[b]噻吩并[2,3-e][1,4]二氮杂革-4-胺化学式
CAS
612503-08-9
化学式
C12H11N3S
mdl
MFCD03411581
分子量
229.305
InChiKey
ZTTWQKYKGNLCCA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    16
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.083
  • 拓扑面积:
    78.6
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2934999090

SDS

SDS:63718d8151165462a1da9aa2b110bfcb
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES<br/>[FR] ARYL BENZODIAZEPINES SUBSTITUEES PAR DE LA PIPERAZINE
    申请人:LILLY CO ELI
    公开号:WO2004014895A1
    公开(公告)日:2004-02-19
    Described herein are compounds of formula (I) wherein: is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, S, and O; Alk is (C1-4) alkylene or hydroxy substituted (C1-4) alkylene; X is oxygen or sulfur; R1 is hydrogen, (C1-6) fluoroalkyl, (C3-6) cycloalkyl, or (C1-4) alkyl, wherein the (C1-4) alkyl is unsubstituted or substituted with hydroxy, methoxy, ethoxy, OCH2CH2OH, or -CN; R2 is H, halogen, (C1-6) fluoroalkyl, (C1-6) cycloalkyl, OR4, SR4, N02, CN, COR4, C(O)OR4, CONR5R6 , NR5R6, S02NR5R6, NR5COR4, NR5SO2R4, optionally substituted aromatic, or (C1-6) alkyl, wherein (C1-6) alkyl is unsubstituted or substituted with a hydroxy group; R3 is hydrogen, (C1-6) fluoroalkyl, (C2-6) alkenyl, Ar, (C1-4)alkyl-Ar, or (C1-4) alkyl wherein (C1-4) alkyl is unsubsituted or substituted with a phenyl; R4 is hydrogen, (C1-6 alkyl, (C1-6) fluoroalkyl, or optionally substituted aromatic; R5 and R6 are independently hydrogen, (C1-6) alkyl, or optionally substituted aromatic, R7 is hydrogen, (C1-6) alkyl, (C1-6) fluoroalkyl, or optionally substituted aromatic; R8 and R9 are independently hydrogen, (C1-6) alkyl, or optionally substituted aromatic; Ar is optionally substituted phenyl, napthyl, monocyclic heteroaromatic or bicyclic heteroaromatic; Z1 and Z2 are independently selected from hydrogen, halogen, (C1-6) alkyl, (C1-6) fluoroalkyl, OR7, SR7, NO2, CN, COR7, CONR8R9, NR8R9, and optionally substituted aromatic; and all salts, solvates, optical and geometric isomers, and crystalline forms thereof. Also, described are the use of the compounds of formula (I) as antagonists of the dopamine D2 receptor and as agents for the treament of psychosis and bipolar disorders, and pharmaceutical formulations of the compounds of formula (I).
    本文描述了以下式(I)的化合物:其中:是一个可选的苯并嵌合的五元或六元芳香环,其中含有从N、S和O中独立选择的零至三个杂原子;Alk是(C1-4)烷基或羟基取代的(C1-4)烷基;X是氧或硫;R1是氢、(C1-6)氟烷基、(C3-6)环烷基或(C1-4)烷基,其中(C1-4)烷基未取代或取代为羟基、甲氧基、乙氧基、OCH2CH2OH或-CN;R2是H、卤素、(C1-6)氟烷基、(C1-6)环烷基、OR4、SR4、N02、CN、COR4、C(O)OR4、CONR5R6、NR5R6、S02NR5R6、NR5COR4、NR5SO2R4、可选取代的芳香基或(C1-6)烷基,其中(C1-6)烷基未取代或取代为羟基;R3是氢、(C1-6)氟烷基、(C2-6)烯基、Ar、(C1-4)烷基-Ar或(C1-4)烷基,其中(C1-4)烷基未取代或取代为苯基;R4是氢、(C1-6)烷基、(C1-6)氟烷基或可选取代的芳香基;R5和R6独立地是氢、(C1-6)烷基或可选取代的芳香基,R7是氢、(C1-6)烷基、(C1-6)氟烷基或可选取代的芳香基;R8和R9独立地是氢、(C1-6)烷基或可选取代的芳香基;Ar是可选取代的苯基、萘基、单环杂芳基或双环杂芳基;Z1和Z2独立地选自氢、卤素、(C1-6)烷基、(C1-6)氟烷基、OR7、SR7、NO2、CN、COR7、CONR8R9、NR8R9和可选取代的芳香基;以及其所有盐、溶剂化合物、光学和几何异构体以及结晶形式。此外,还描述了将上述式(I)的化合物用作多巴胺D2受体拮抗剂以及用于治疗精神病和双相情感障碍的药剂,以及上述式(I)的药物配方。
  • [EN] PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS<br/>[FR] ARYLES BENZODIAZEPINES A SUBSTITUTION DE PIPERAZINE ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DE RECEPTEUR DE DOPAMINE DANS LE TRAITEMENT DE TROUBLES PSYCHOTIQUES
    申请人:LILLY CO ELI
    公开号:WO2003082877A1
    公开(公告)日:2003-10-09
    Described herein are antipyschotic compounds of formula (I) wherein, A is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, O, and S; Alk is (C1-4) alkylene optionally substituted with OH, methoxy, ethoxy, or F; Ar is optionally substituted phenyl, naphthyl, monocyclic heteroaromatic, or bicyclic heteroaromatic; R1 is hydrogen or (C1-4) alkyl optionally substituted with OH, OR3, or OCH2CH2OH, wherein R3 is (C1-2) alkyl; R2 is H, (C1-6) alkyl, halogen, fluorinated (C1-6) alkyl, OR4, SR4, NO2, CN, COR4, CONR5R6, SO2NR5R6, NR5R6, NR5COR4, NR5SO2R4, or optionally substituted phenyl,wherein R4 is hydrogen, (C1-6) alkyl, fluorinated (C1-6) alkyl, benzyl, or optionally substituted phenyl, R5 and R6 are independently hydrogen, (C1-6) alkyl, or optionally substituted phenyl; Z is one or two substituents independently selected from hydrogen, halogen, (C1-6) alkyl, fluorinated (C1-6) alkyl, OR7, SR7, NO2, CN, COR7, CONR8R9, SO2NR8R9, NR8SO2R7, NR8R9, or optionally substituted phenyl, wherein R7 is hydrogen, (C1-6) alkyl, fluorinated (C1-6) alkyl, benzyl, or optionally substituted phenyl, R8 and R9 are independently hydrogen, (C1-6) alkyl, or optionally substituted phenyl; and salts, solvates, and crystal forms thereof. Also described are the use of the compounds of formula (I) as antagonists of the dopamine D2 receptor and as agents for the treatment of psychosis and bipolar disorders, and pharmaceutical formulations of the compounds of formula (I). Also described are compounds useful as intermediates for the synthesis of the compounds of formula (I).
    本文描述了公式(I)的抗精神药物化合物,其中,A是一个可选的苯并嵌有零至三个异原子(N、O和S)的五元或六元芳香环;Alk是(C1-4)烷基烯,可选地取代为OH、甲氧基、乙氧基或F;Ar是可选取代的苯基、萘基、单环杂芳基或双环杂芳基;R1是氢或(C1-4)烷基,可选地取代为OH、OR3或OCH2CH2OH,其中R3是(C1-2)烷基;R2是H、(C1-6)烷基、卤素、氟代(C1-6)烷基、OR4、SR4、NO2、CN、COR4、CONR5R6、SO2NR5R6、NR5R6、NR5COR4、NR5SO2R4或可选取代的苯基,其中R4是氢、(C1-6)烷基、氟代(C1-6)烷基、苄基或可选取代的苯基,R5和R6独立地是氢、(C1-6)烷基或可选取代的苯基;Z是一个或两个取代基,独立地选自氢、卤素、(C1-6)烷基、氟代(C1-6)烷基、OR7、SR7、NO2、CN、COR7、CONR8R9、SO2NR8R9、NR8SO2R7、NR8R9或可选取代的苯基,其中R7是氢、(C1-6)烷基、氟代(C1-6)烷基、苄基或可选取代的苯基,R8和R9独立地是氢、(C1-6)烷基或可选取代的苯基;以及其盐、溶剂合物和晶型。还描述了将公式(I)的化合物用作多巴胺D2受体拮抗剂和治疗精神病和双相障碍的药物,以及公式(I)的化合物的制剂。还描述了作为公式(I)化合物合成的中间体有用的化合物。
  • [EN] ANTIBODIES TO OLANZAPINE HAPTENS AND USE THEREOF<br/>[FR] ANTICORPS DIRIGÉS CONTRE DES HAPTÈNES D'OLANZAPINE ET LEUR UTILISATION
    申请人:ORTHO CLINICAL DIAGNOSTICS INC
    公开号:WO2014031656A1
    公开(公告)日:2014-02-27
    Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.
    揭示了一种与奥氮平结合的抗体,可用于在样本中检测奥氮平,例如在竞争性免疫分析方法中。该抗体可用于侧向流动测定装置,用于奥氮平的现场检测,包括在单个侧向流动测定装置中多重检测阿立哌唑、奥氮平、奎硫平和利培酮。
  • [EN] HAPTENS OF OLANZIPINE<br/>[FR] HAPTÈNES DE L'OLANZIPINE
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2014031587A1
    公开(公告)日:2014-02-27
    The invention relates to compounds of Formula I, wherein R1, R2, and R3 are defined in the specification, useful for the synthesis of novel conjugates and immunogens derived from olanzapine. The invention also relates to conjugates of an olanzapine hapten and a protein.
    这项发明涉及到式I的化合物,其中R1、R2和R3在规范中有定义,用于合成源自奥兰扎平的新型共轭物和免疫原。该发明还涉及奥兰扎平半抗原和蛋白质的共轭物。
  • [EN] A PROCESS FOR PRODUCING PURE FORM OF 2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-THIENO[2,3-b][1,5]BENZODIAZEPINE<br/>[FR] PROCEDE PERMETTANT DE PRODUIRE UNE FORME PURE DE 2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-THIENO[2,3-B][1,5]BENZODIAZEPINE
    申请人:JUBILANT ORGANOSYS LTD
    公开号:WO2006006180A1
    公开(公告)日:2006-01-19
    Disclosed is a process for producing pure form of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-­thieno[2,3-b][1,5] benzodiazepine. The process comprises of reacting 2-(2-aminoanilino)-5-­methylthiophene-3-carbonitrile with N-methyl piperazine in conjunction with N-methylpiperazine acid salt, to produce 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine. Also disclosed is a process for obtaining the Polymorphic Form I of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine by crystallizing the crude 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine in a mixture of solvents.
    揭示了一种生产纯2-甲基-4-(4-甲基-1-哌嗪基)-10H-噻吩[2,3-b][1,5]苯二氮杂环己烯的方法。该方法包括将2-(2-氨基苯胺基)-5-甲基噻吩-3-碳腈与N-甲基哌嗪和N-甲基哌嗪酸盐一起反应,以产生2-甲基-4-(4-甲基-1-哌嗪基)-10H-噻吩[2,3-b][1,5]苯二氮杂环己烯。还揭示了通过在溶剂混合物中结晶粗2-甲基-4-(4-甲基-1-哌嗪基)-10H-噻吩[2,3-b][1,5]苯二氮杂环己烯来获得2-甲基-4-(4-甲基-1-哌嗪基)-10H-噻吩[2,3-b][1,5]苯二氮杂环己烯的多形式I的方法。
查看更多